R
Roman Hájek
Researcher at University of Ostrava
Publications - 688
Citations - 21002
Roman Hájek is an academic researcher from University of Ostrava. The author has contributed to research in topics: Multiple myeloma & Bortezomib. The author has an hindex of 56, co-authored 625 publications receiving 16135 citations. Previous affiliations of Roman Hájek include Masaryk University & Palacký University, Olomouc.
Papers
More filters
Journal ArticleDOI
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
Courtney D. DiNardo,Brian A. Jonas,Vinod Pullarkat,Michael J. Thirman,Jacqueline S. Garcia,Andrew H. Wei,Marina Konopleva,Hartmut Döhner,Anthony Letai,Pierre Fenaux,Elizabeth A. Koller,Violaine Havelange,Brian Leber,Jordi Esteve,Jianxiang Wang,Vlatko Pejša,Roman Hájek,Kimmo Porkka,Árpád Illés,David Lavie,Roberto M. Lemoli,Kazuhito Yamamoto,Sung-Soo Yoon,Jun-Ho Jang,Su-Peng Yeh,Mehmet Turgut,Wan-Jen Hong,Ying Zhou,Jalaja Potluri,Keith W. Pratz +29 more
TL;DR: In previously untreated patients with confirmed AML who were ineligible for intensive chemotherapy, overall survival was longer and the incidence of remission was higher among patients who received azacitidine plus venetoclax than among those who received zsitidine alone.
Journal ArticleDOI
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders
Angela Dispenzieri,Robert A. Kyle,Giampaolo Merlini,Jesús F. San Miguel,Heinz Ludwig,Roman Hájek,Antonio Palumbo,Sundar Jagannath,J. Bladé,Sagar Lonial,Meletios A. Dimopoulos,Raymond L. Comenzo,H. Einsele,Bart Barlogie,KC Anderson,Morie A. Gertz,J L Harousseau,M. Attal,Patrizia Tosi,Pieter Sonneveld,Mario Boccadoro,Gareth J. Morgan,Paul G. Richardson,O. Sezer,Maria-Victoria Mateos,Michele Cavo,Douglas E. Joshua,Ingemar Turesson,Wenming Chen,K. Shimizu,R. L. Powles,S V Rajkumar,Brian G.M. Durie +32 more
TL;DR: Consensus guidelines for the use of the serum immunoglobulin-free light chain assay are provided, in the diagnosis and management of clonal PCD.
Journal ArticleDOI
Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma
Antonio Palumbo,Roman Hájek,Michel Delforge,Martin Kropff,Maria Teresa Petrucci,John Catalano,Heinz Gisslinger,Wieslaw Wiktor-Jedrzejczak,Mamia Zodelava,Katya C Weisel,Nicola Cascavilla,Genadi Iosava,Michele Cavo,Janusz Kloczko,Joan Bladé,Meral Beksac,Ivan Spicka,Torben Plesner,Joergen Radke,Christian Langer,Dina Ben Yehuda,Alessandro Corso,Lindsay Herbein,Zhinuan Yu,Jay Mei,Christian Jacques,Meletios A. Dimopoulos +26 more
TL;DR: MPR-R significantly prolonged progression-free survival in patients with newly diagnosed multiple myeloma who were ineligible for transplantation, with the greatest benefit observed in patients 65 to 75 years of age.
Journal ArticleDOI
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study
Meletios A. Dimopoulos,Philippe Moreau,Antonio Palumbo,Douglas E. Joshua,Ludek Pour,Roman Hájek,Thierry Facon,Heinz Ludwig,Albert Oriol,Hartmut Goldschmidt,Laura Rosiñol,Jan Straub,Aleksandr Suvorov,Carla Araujo,Elena Rimashevskaya,Tomas Pika,Gianluca Gaidano,Katja Weisel,Vesselina Goranova-Marinova,Anthony P. Schwarer,Leonard Minuk,Tamas Masszi,Ievgenii Karamanesht,Massimo Offidani,Vania Hungria,Andrew Spencer,Robert Z. Orlowski,Heidi H. Gillenwater,Nehal Mohamed,Shibao Feng,Wee Joo Chng +30 more
TL;DR: The primary endpoint was progression-free survival in the intention-to-treat population and carfilzomib with dexamethasone could be considered in patients with relapsed or refractory multiple myeloma.
Journal ArticleDOI
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management
Robert A. Kyle,Brian G.M. Durie,S V Rajkumar,Ola Landgren,J. Bladé,Giampaolo Merlini,N Kröger,H. Einsele,David H. Vesole,Meletios A. Dimopoulos,J F San Miguel,Hervé Avet-Loiseau,Roman Hájek,Wenming Chen,Kenneth C. Anderson,Heinz Ludwig,Pieter Sonneveld,Santiago Pavlovsky,Antonio Palumbo,Paul G. Richardson,Bart Barlogie,P R Greipp,Robert Vescio,Ingemar Turesson,Jan Westin,Mario Boccadoro +25 more
TL;DR: Monoclonal gammopathy of undetermined significance (MGUS) was identified in 3.2% of residents of Olmsted County, Minnesota, 50 years of age or older and is characterized by having an M protein <15 g/l, IgG type and a normal free light chain (FLC) ratio.